1. Search Result
Search Result
Results for "

ventral prostate

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

1

Natural
Products

3

Recombinant Proteins

1

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-17375
    Allylestrenol
    1 Publications Verification

    Progesterone Receptor Androgen Receptor Endocrinology
    Allylestrenol is an orally active synthetic anti-androgen sexualsteroid. Allylestrenol can prevent miscarriage in vivo. Allylestrenol significantly affects testosterone progesterone level in rat model. Allylestrenol can reduce ventral prostate weight in rat model .
    Allylestrenol
  • HY-N13195

    5 alpha Reductase Others
    (15α)-15,26-Dihydroxylanosta-7,9(11),24-trien-3-one shows a 5a-reductase inhibitory activity with an IC50 value of 41.9 μM. (15α)-15,26-Dihydroxylanosta-7,9(11),24-trien-3-one inhibits the growth of the ventral prostate induced by testosterone in rat. (15α)-15,26-Dihydroxylanosta-7,9(11),24-trien-3-one is promising for research of benign prostatic hyperplasia (BPH) as well as other 5α-dihydrotestosterone (DHT)-related disorders, such as acne and male pattern baldness .
    (15α)-15,26-Dihydroxylanosta-7,9(11),24-trien-3-one
  • HY-17375R

    Progesterone Receptor Reference Standards Androgen Receptor Endocrinology
    Allylestrenol (Standard) is the analytical standard of Allylestrenol. This product is intended for research and analytical applications. Allylestrenol is an orally active synthetic anti-androgen sexualsteroid. Allylestrenol can prevent miscarriage in vivo. Allylestrenol significantly affects testosterone progesterone level in rat model. Allylestrenol can reduce ventral prostate weight in rat model .
    Allylestrenol (Standard)
  • HY-116219

    Androgen Receptor Endocrinology Cancer
    WB2838 is a non-steroidal androgen-receptor antagonist (IC50: 0.8 μM for partially purified rat prostate cytosol receptor). WB2838 exhibits anti-cancer activity against androgen-responsive breast cancer. WB2838 also shows the inhibitory activity against the growth of the ventral prostate induced by Testosterone propionate .
    WB2838
  • HY-180409

    Androgen Receptor Cancer
    YM580 is a potent, orally active and selective Androgen Receptor (AR) antagonist (IC50 = 0.11 μM, hAR Ki = 4.6 nM, rAR Ki = 6.2 nM). YM580 exhibits good selectivity over PR, GR, and ERα (Kis > 3300 nM). YM580 decreases ventral prostate weight in mature intact rats dose-dependently without affecting serum testosterone levels. YM580 can be used for the research of prostate cancer .
    YM580
  • HY-119436

    Androgen Receptor Metabolic Disease
    LG-120907 is a selective androgen receptor (AR) antagonist with a Ki value of 26 nM. LG-120907 inhibits Testosterone-induced increases in ventral prostate (VP) tissue weight and seminal vesicles (SV) tissue weight in vivo .
    LG-120907
  • HY-180410

    Androgen Receptor Endocrinology
    YM-1758735 is an orally active androgen receptor (AR) antagonist with an IC50 of 0.2 μM. YM-1758735 inhibits AR-mediated transcriptional activation. YM-1758735 can be used for the research of prostate .
    YM-1758735

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: